

NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, INTO THE UNITED STATES OF AMERICA OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION WOULD BE UNLAWFUL

The presentation has been prepared by Xlife Sciences Ltd. ("Xlife", and together with its subsidiaries, the "Xlife Group") for information and background purposes only. This document is not, and should not be construed as, a prospectus or offering document, and has not been reviewed or approved by any regulatory or supervisory authority. The information does not constitute or form part of, and should not be construed as, an offer for sale or subscription of, or a solicitation or invitation of any offer to subscribe for or purchase any loans or securities of or make an investment in Xlife or any other member of the Xlife Group or any other entity in any jurisdiction, and nothing contained therein shall form the basis of, or be relied on in connection with, any contract or commitment whatsoever, in particular, it must not be used in making any investment decision.

No representation, warranty or undertaking, express or implied, is made by Xlife or any member of the Xlife Group or any of their respective affiliates or directors, officers, employees, agents or advisers ("Representatives") or any other person as to, and no reliance should be placed on, the fairness, accuracy, completeness or correctness of the information or the opinions contained therein or any other statement made or purported to be made in connection with Xlife, the Xlife Group or any member thereof, for any purpose whatsoever, including but not limited to any investment considerations. No responsibility, obligation or liability whatsoever, whether arising in tort, contract or otherwise, is or will be accepted by Xlife or any member of the Xlife Group or any of their respective Representatives or any other person for any loss, cost or damage howsoever arising from any use of the information, or for information or opinions or for any errors, omissions or misstatements contained therein or otherwise arising in connection therewith.

This presentation contains forward-looking statements, including but not limited to, projections of financial developments, market activities, future performance of products and solutions or planned transactions, which involve risks and uncertainties and are based on certain assumptions. These forward-looking statements are subject to change based on known or unknown risks and various other factors, which could cause the actual results, performance or events to differ materially from the statements made herein. If any of these risks and uncertainties materializes or if the assumptions underlying any of Xlife's forward-looking statements prove to be incorrect, the actual results may be materially different from those Xlife expresses or implies by such statements. Xlife does not intend or assume any obligation to update these forward-looking statements since they are based solely on the circumstances at the date of their publication.

The securities mentioned herein will not be registered under the United States Securities Act of 1933, as amended (the "Act"), and such securities may not be offered or sold in the United States of America absent registration or an applicable exemption from registration requirements under the Act. This presentation is not a prospectus for the purposes of Regulation (EU) 2017/1129 (as amended) and Regulation (EU) 2017/1129 as it forms part of domestic law pursuant to the European Union (Withdrawal) Act 2018.

COMPANY OVERVIEW

Xlife Sciences is a Swiss life sciences incubator and accelerator.

2019

LAUNCH
WITH 6 PROJECT COMPANIES

1

STOCK EXCHANGE
SPARKS SEGMENT SIX SWISS EXCHANGE
SINCE FEBRUARY 2022,
PREVIOUS MUNICH STOCK EXCHANGE

~5.77 M

SHARES
5.767.572 SHARES WITH A NOMINAL
VALUE OF CHF 1

50.2%

FREE FLOAT
42,8% FOUNDERS, 7% MANAGEMENT

~85 M

MARKET CAPITALIZATION
September 2026

>40/100k

INNOVATION PARTNERS
WITH UNIVERSITIES, RESEARCH
INSTITUTIONS & INDUSTRY PARTNERS /
ACCESS TO SCIENTISTS

19/4/33

PORTFOLIO COMPANIES
IN 4 INVESTMENT PILLARS
WITH 33 PROJECTS

>20

EMPLOYEES
XLIFE SCIENCES AG /
PROJECT COMPANIES

Xlife Sciences supports researchers and entrepreneurs in positioning, structuring, developing and implementing their concepts.

~300

INVENTION DISCLOSURES P.A.

~3-5

NEW PROJECT COMPANIES P.A.

~1.5 M

FINANCING

~500k

POTENTIAL GRANTS

WHERE WE ADD VALUE TO OUR PROJECT COMPANIES

PROOF OF
CONCEPT

M&A

MARKETING

HR

STRUCTURING


BUSINESS
DEVELOPMENT

RESEARCH

PATENTING

LICENSING

BREAKDOWN BY PROJECT DEVELOPMENT PHASE




EXIT STRATEGIES

LICENSE DEAL

TRADE SALE

IPO

INVESTMENT PROCESS



MANAGEMENT



Oliver R. Baumann
Chief Executive Officer



Carl von Halem
Chief Financial Officer



Dr. Alexander Zink
Chief Scientific Officer



Dr. Frank Plöger
MD Xlife Sciences USA



Christian Faber
Head of Legal & Compliance



Beat Kläui
Head of Accounting and Taxes

BOARD OF DIRECTORS



David L. Deck
President of the Board of Directors



Désirée A. Dosch
Member of the Board of Directors



Dr. Norbert Windhab
Member of the Board of Directors



Mark S. Müller
Member of the Board of Directors



Oliver R. Baumann
Member of the Board of Directors



Prof. Dr. habil. Michael B. Klein
Politics Expert



Prof. Dr. Ernst Rietschel
Immunology Expert



Prof. Dr. Hans-Georg Rammensee
Immunology Expert



Prof. Dr. Johannes Schumacher
Human Genetics Expert



Dr. Christoph Brucher
Industry Expert



Dr. med. Uwe Rudolf
Max Reuter, DM
Head Physician at Klinik Im Leben



Dr. med. Ralf Oettmeier
Head Physician at Alpstein Clinic



Dr. Bernward Garthoff
Industry Expert



Prof. Dr. Jürgen Eckel
Diabetes Expert




Prof. Dr. Ulrich Räh
Industry Expert

ADVISORY BOARD

KEY FOCUS AREAS & PROJECT COMPANIES

 TECHNOLOGY PLATFORMS				
 BIOTECH & THERAPIES				
 MEDICAL TECHNOLOGY				
 ARTIFICIAL INTELLIGENCE				

ONCOLOGY	METABOLIC / INFLAMMATION	MEDICAL DEVICES	3D-PRINTING	DIAGNOSTICS	OBESITY
    	     	 		 	 

Our approach is to be in the driver seat. In over 50% of the new project companies, Xlife Sciences initiated the spin-off process directly from and with a university or research institution.



PROJECT STAGE

TECHNOLOGY PLATFORMS

	XLIFE	R&D	POC	EXIT
 INVENTUMGENETICS	2021	→		
 inflamed pharma	2019	→	→	
 Palleos	2019	→	→	
 VERAXA	2020	→	→	→

BIOTECH & THERAPIES

	XLIFE	R&D	POC	EXIT
 alytas therapeutics	2019	→		
 BALIOPHARM	2021	→	→	
 Synimmune antibodies for life	2019	→	→	→
 Lysatpharma.	2019	→	→	
 FIRSTGENE	2020	→		
 QUADIRABIOSCIENCES	2021	→	→	
 xarma life sciences	2020	→		
 XRNA BIOTECH	2023	→		


ARTIFICIAL INTELLIGENCE

	XLIFE	R&D	POC	EXIT
 FUSE-AI	2019	→	→	→
 XDIAGNOSTICS	2021	→	→	→

MEDTECH & DIAGNOSTIC

	XLIFE	R&D	POC	EXIT
 axenoll 3D printing for life	2019	→	→	
 LAXXON MEDICAL technology for your life	2019	→	→	→
 Saniva	2019	→	→	
 vitruvia WE SUSTAIN ADDED VALUES	2019	→	→	
 nova xomx	2022	→		
 Xkidney	2019	→	→	→
 X nuclear	2020	→	→	→

Xlife Sciences has a recent focus on DACH. In the course of various business development activities, the network has expanded into EMEA, Asia and the US.




BUSINESS PARTNERS


Xlife Sciences is built on long-term relationships and a growing network with inventors, leading universities and scientific institutions.



Xlife Sciences synergies are a key driver of success. In the Xlife family, we live synergies. Many use cases and agreements have grown genuinely between our partners.



VERAXA BIOTECH – FROM LAB TO NASDAQ



Envolvement Xlife Sciences



Fusion
initiated



Fundraising
(~USD 80M)



Board member



SPAC-
identification



Investor relations



Listing &
expansion

Our motivations is to integrate ESG in the whole group, to incorporate personal values and to make a positive impact. Please find [here](#) our current ESG-Report and Code of Conduct.




NEXT STEPS & FOCUS

Having built up the portfolio over the last few years, the main task now is to achieve successful exits with project companies, strengthen liquidity and continue to grow.



**CASH
EVENTS**



**BRAND
AWARENES
S**



**ENHANCE
PIPELINE**



**INCREASE
LIQUIDITY**



**STRENGTHEN
TEAM**

STATUS QUO PROJECTS

Portfolio companies	Shares XLS (%)	Xlife stage	Focus	Next steps
 alytas therapeutics	51	R&D	Antibodies for the treatment of obesity	License deal Asia In-vivo POC Commercialization
 VERAXA	18	Exit	Antibody-based cancer therapies	Listing NASDAQ Cash-event Xlife Sciences
 inflamed pharma	70	Exit	Solubility enhancement of poorly soluble APIs	License deal Asia Further license deals
 FUSE-AI	44	Exit	AI-assisted solution for medical imaging	Roll-out Europe FDA-approval Setup listing
 nuclear	100	Exit	Liver-specific PET-Tracer	Roll-out DACH M&A transaction
 INVENTUMGENETICS	100	R&D	Therapeutic solutions based on human genetic data	Preclinical validation Expansion business model
 Palleos	50	Exit	Clinical full-service-CRO	Increase market share Expansion USA
 Lysatpharma.	25	POC	Exosomes derived from blood-conserves	Preclinical validation M&A transaction
 Saniva	19	POC	Screening for early diagnosis of neurodegenerative diseases	Finalize clinical study M&A transaction
 axenoll 3D printing for life	14	POC	3D screen printing of biomaterials	Roll-out cosmetics ISO-certification M&A transaction

STATUS QUO PROJECTS

Portfolio companies	Shares XLS (%)	Xlife stage	Focus	Next steps
 BALIOPHARM	Others	Exit	Atrosimab: antibody for the treatment of inflammatory diseases	License deal big pharma
 FIRSTGENE	70	Start	Tissue-specific gene therapies	Animal model Proof of concept
 QUADIRABIOSCIENCES	50	POC	Improvement of ADCs	M&A transaction
 xarma life sciences	46	R&D	Bispecific antibodies	Utilization patent for bispecifics platform
 XRNA BIOTECH	100	Start	RNA-based therapeutic targets	Restart of the project together with inventor
 vitruvia WE SUSTAIN ADDED VALUES	5	POC	Production, repair, trade of medical devices	Passive
 noua xomx	40	R&D	Exosomes for regenerative medicine	Finalization current study
 Xkidney	100	Exit	Biomarker for chronic kidney diseases	License deal Asia Grants Technology advancement

VALUE INFLECTION POINTS

We intend to carry out numerous projects as a license deal, trade sale or IPO. Below potential monetization events divided in two phases from near to mid-term future.




WHY XLIFE SCIENCES

With Xlife Sciences, we enable our shareholders to invest directly in a diversified early-stage life sciences portfolio in a liquid asset.



**LEAN AND COST-
EFFECTIVE
STRUCTURE**



**ACCESS TO A
DIVERSIFIED
PORTFOLIO**



**LIQUID
ASSET**



**DISCOUNTED
TRADE**

PLEASE GET IN TOUCH



> Oliver R. Baumann

Chief Executive Officer

oliver.baumann@xlifesciences.ch

+41 44 385 84 60

> Carl v. Halem

Chief Financial Officer

carl.halem@xlifesciences.ch

+41 44 385 84 58

> Dr. Alexander Zink

Chief Scientific Officer

alexander.zink@xlifesciences.ch

+41 44 385 84 60

> Dr. Frank Plöger

MD Xlife Sciences USA

frank.ploeger@xlifesciences.ch

+41 44 385 84 60

where innovation leads to success

